Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Sweden Joins Campaign for Post-Brexit Host of EMA



Sweden joins multiple other countries, including France, Spain and Poland, which are bidding to be the new home of the regulatory agency, post-Brexit.

Share this!

December 14, 2016 | by Sarah Hand, M.Sc.

Last week, the Swedish government joined the competition to become the new host country of the European Medicines Agency (EMA). Sweden joins multiple other countries, including France, Spain and Poland, which are bidding to be the new home of the regulatory agency, post-Brexit.

Currently, the EMA is headquartered in London, England, however this will need to change as the country has voted to leave the European Union (EU). Denmark, Italy and Ireland have also nominated themselves for the position.

“With one of Europe's top national medicines agencies, an excellent climate for research and life science as well as good conditions for an efficient relocation, Sweden is a good future home for the EMA,” said Gabriel Wikstrom, Sweden’s Health Care Minister, in a statement. By having the EMA close to Sweden’s capital Stockholm, the country could see a major boost in the pharmaceutical and biotech sectors.

Sweden lost a major player in the industry when multinational pharmaceutical company AstraZeneca relocated its headquarters to England. Still, the country boasts a number of small medtech companies who thrive in the country’s startup environment.

Sweden is already the home of the European Centre for Disease Prevention and Control (ECDC), which could make it a logical choice for the new site of the EMA. The EMA comprises over 900 employees, which will eventually need to be relocated with minimal effect on day-to-day operations including drug approvals.

As the UK has yet to start the process of exiting from the EU, the decision of where the EMA should be based is unlikely to be made anytime soon. In June of this year, 52 percent of the UK voted in favour of leaving the EU.

Keywords: Brexit, EMA, Regulatory Agency


Share this with your colleagues!

Amgen Identifies Issue with Patient Access to PCSK9 Inhibitor

March 23, 2017 - Most US patients hoping to get their PCSK9 inhibitor medications covered by their prescription drug plan are being denied, according to two new studied conducted by Amgen.

Featured In: Biotech News

Smartphone App Created Using Apple’s ResearchKit Used to Conduct Asthma Clinical Studies

March 22, 2017 - Researchers at the Icahn School of Medicine at Mount Sinai have conducted a large-scale, observational study of asthma patients using the Apple ResearchKit framework and the Asthma Health app on patients’ iPhones.

Featured In: Clinical Trials News

IBS Patients Taking Viberzi May Be at Increased Risk of Pancreatitis

March 22, 2017 - According to a recent drug safety communication issued by the US Food and Drug Administration (FDA), patients with irritable bowel syndrome (IBS) with diarrhea should not be treated using Viberzi (eluxadoline), if they do not have a gallbladder.

Featured In: Drug Safety News


Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?


How to Improve the Speed and Efficiency of Your Clinical Trials

High Performance Computing for High Content Screening - A Case Study

The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review

Treatment of Psoriasis: Improvements Through Clinical Trials

Copyright © 2016-2017 Honeycomb Worldwide Inc.